术中MRI在胶质瘤手术中的疗效与安全性:前瞻性随机对照试验的系统综述与Meta分析
该系统综述与Meta分析检索PubMed、Embase和Cochrane Reviews数据库至2024年2月底,纳入3项前瞻性随机对照试验共384例患者,评估术中MRI引导胶质瘤手术的疗效与安全性。术中MRI引导手术在全切除率上优于常规导航引导手术(OR 5.40,95%CI 3.25-8.98;p<0.00001),且术后神经功能恶化与对照组相等(OR 1.0,95%CI 0.6-1.7;p=0.91,I²=0%),但平均延长手术42分钟(95%CI 3.3-80.7分钟;p=0.03,I²=56%)。
要点
- 术中MRI引导胶质瘤手术的全切除率显著优于常规导航引导手术(OR 5.40,95%CI 3.25-8.98;p<0.00001)。
- 术中MRI组与对照组术后神经功能恶化无显著差异(OR 1.0,95%CI 0.6-1.7;p=0.91,I²=0%)。
- 术中MRI平均延长手术42分钟(95%CI 3.3-80.7分钟;p=0.03,I²=56%),术后颅内出血风险未增加(OR 1.9,95%CI 0.2-16.9;p=0.55,I²=0%)。
核心结论
- 术中MRI在实现胶质瘤全部强化肿瘤部分完全切除方面优于常规手术,延长无进展生存期且不增加风险。
- 术中MRI是一种有助于实现上述目标且不降低神经功能缺损和手术并发症方面安全性的工具。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Cochrane Reviews数据库至2024年2月底,纳入3项前瞻性随机对照试验共384例患者。
- 终点包括切除范围、无进展生存期、总生存期、神经功能和手术并发症;采用R包IPDfromKM重建无进展生存期的个体患者数据。
主要发现
- 从1923条识别结果中,3项随机对照试验共384例患者符合纳入标准。
- 术中MRI病例中29.2%进行了扩大切除。
- 术中MRI引导胶质瘤手术在实现全切除方面优于常规导航引导手术(OR 5.40,95%CI 3.25-8.98;p<0.00001)。
- 达到全切除的患者中位进展时间为16.0个月(95%CI 12.3-19.7个月),而次全切除患者的中位无进展生存期为9.7个月(95%CI 6.9-12.5个月)(p<0.001)。
- 尽管全切除率提高,术后神经功能恶化在术中MRI组与对照组之间相等(OR 1.0,95%CI 0.6-1.7;p=0.91,I²=0%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Maximum extent of resection in glioma yields enhanced survival outcomes. The contemporary literature presents contradictory results regarding the benefit of intraoperative MRI (iMRI). This meta-analysis aimed to investigate the efficacy and safety of iMRI-guided surgery. METHODS: The authors searched the PubMed, Embase, and Cochrane Reviews databases for eligible prospective randomized controlled trials through the end of February 2024. Endpoints were extent of resection, progression-free survival (PFS), overall survival, neurological functioning, and surgical complications. Individual patient data regarding PFS were reconstructed using the R package IPDfromKM. RESULTS: From 1923 identified results, 3 randomized controlled trials with 384 patients met the inclusion criteria. Extended resections after iMRI were performed in 29.2% of the iMRI cases. Intraoperative MRI-guided glioma surgery (OR 5.40, 95% CI 3.25-8.98; p < 0.00001) outperformed conventional navigation-guided surgery in attaining gross-total resection (GTR). In patients in whom a GTR was achieved, the median time to progression was 16.0 months (95% CI 12.3-19.7 months), while the median PFS in patients with a subtotal resection was 9.7 months (95% CI 6.9-12.5 months) (p < 0.001). Despite increased GTR rates, postoperative neurological deterioration was equal among the iMRI and control groups (OR 1.0, 95% CI 0.6-1.7; p = 0.91, I2 = 0%). Intraoperative MRI use prolongs surgery by 42 minutes on average (95% CI 3.3-80.7 minutes; p = 0.03, I2 = 56%). The risk of postoperative intracranial hemorrhage (OR 1.9, 95% CI 0.2-16.9; p = 0.55, I2 = 0%) was not increased, while in one study significantly increased infections were observed in the iMRI arm. CONCLUSIONS: Intraoperative MRI outperforms conventional surgery in achieving complete glioma resections of all contrast-enhancing tumor portions, enhancing PFS without added risk. Intraoperative MRI is a tool that facilitates these aims without reducing safety in terms of neurological deficits and surgical complications.
引用
- Wach J, Vychopen M, Basaran AE, et al. Efficacy and safety of intraoperative MRI in glioma surgery: a systematic review and meta-analysis of prospective randomized controlled trials. J Neurosurg. 2024. PMID: 39642374. doi:10.3171/2024.7.JNS241102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。